These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34911359)

  • 41. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
    Wiecek W; Karcher H
    PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    Chan SL; Ryoo BY; Mo F; Chan LL; Cheon J; Li L; Wong KH; Yim N; Kim H; Yoo C
    J Hepatol; 2024 Aug; 81(2):258-264. PubMed ID: 38570034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
    Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
    Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
    Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
    Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
    Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
    Osanto S; van der Hulle T
    Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
    Tomita Y; Tatsugami K; Nakaigawa N; Osawa T; Oya M; Kanayama H; Nakayama Kondoh C; Sassa N; Nishimura K; Nozawa M; Masumori N; Miyoshi Y; Kuroda S; Tanaka S; Kimura A; Tamada S
    Int J Urol; 2020 Nov; 27(11):952-959. PubMed ID: 32789967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
    Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
    J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
    Choueiri TK; Powles T; Albiges L; Burotto M; Szczylik C; Zurawski B; Yanez Ruiz E; Maruzzo M; Suarez Zaizar A; Fein LE; Schutz FA; Heng DYC; Wang F; Mataveli F; Chang YL; van Kooten Losio M; Suarez C; Motzer RJ;
    N Engl J Med; 2023 May; 388(19):1767-1778. PubMed ID: 37163623
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
    Choueiri TK; Hessel C; Halabi S; Sanford B; Michaelson MD; Hahn O; Walsh M; Olencki T; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; George D; Morris MJ
    Eur J Cancer; 2018 May; 94():115-125. PubMed ID: 29550566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
    Schmidinger M; Danesi R
    Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.
    McGregor B; Mortazavi A; Cordes L; Salabao C; Vandlik S; Apolo AB
    Cancer Treat Rev; 2022 Feb; 103():102333. PubMed ID: 35033866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cabozantinib improves clinical outcomes in renal cancer.
    Das M
    Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
    [No Abstract]   [Full Text] [Related]  

  • 56. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program.
    Prisciandaro M; Ratta R; Massari F; Fornarini G; Caponnetto S; Iacovelli R; De Giorgi U; Facchini G; Scagliarini S; Sabbatini R; Caserta C; Peverelli G; Mennitto A; Verzoni E; Procopio G
    Am J Clin Oncol; 2019 Jan; 42(1):42-45. PubMed ID: 30204614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
    Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
    Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials.
    McElwee JH; Gourdin TS; Mikoll J; Weeda E; Sion AM
    J Oncol Pharm Pract; 2020 Jun; 26(4):861-865. PubMed ID: 31566113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.